News | October 12, 2008

TAXUS Express Stent Shows Low Re-Intervention Rates in Patients With, Without Diabetes

October 13, 2008 – At TCT 2008, Boston Scientific Corp. announced results from an analysis of nearly 7,500 patients from its TAXUS ARRIVE 1 and 2 registries, which are designed to confirm the performance of the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System in real-world practice.

The two-year pooled ARRIVE data showed that the TAXUS Stent reduced clinical restenosis in patients with diabetes as effectively as in patients without diabetes, with no incremental risk of myocardial infarction (MI) or stent thrombosis. Analysis of the data was presented by John M. Lasala, M.D., Ph.D., F.A.C.C.

“The ARRIVE diabetic subset data demonstrated that the TAXUS Stent mitigated the adverse effect of diabetes as a risk factor for restenosis and repeat procedures in the patients studied," said Dr. Lasala, professor of medicine, Washington University School of Medicine in St. Louis. “While the diabetic patients had more cardiac risk factors, comorbidity and higher mortality than non-diabetics, the rates of reintervention, MI and stent thrombosis in the ARRIVE 1 and 2 registries were similar in both groups, regardless of risk profile.”

The pooled analysis included two-year data on 2,112 medication-requiring diabetic patients and 5,380 non-diabetic patients from the ARRIVE registry program. The population was further segmented into a higher-risk group (1) and a lower-risk group. Due to a significant increase in comorbid risk factors in patients with diabetes compared to non-diabetics, multivariate modeling and analysis was used to allow for adjustment of baseline differences (other than the presence of diabetes) between the two groups. Multivariate analysis was also used to determine predictors of target lesion revascularization (TLR) and mortality.

In the pooled ARRIVE 1 and 2 registry analysis, the TAXUS Stent maintained comparable re-intervention rates in the diabetic and non-diabetic patient populations. Cumulative two-year TLR rates, whether adjusted (7.1 percent vs. 6.8 percent, p=0.41) or unadjusted (8.2 percent vs. 7.7 percent, p=0.59), were similar between diabetic and non-diabetic patients, respectively. Diabetic patients in the higher-risk subgroup actually had lower adjusted TLR rates than non-diabetic patients (7.2 percent vs. 8.6 percent, p=0.03). Analysis of multivariate predictors showed that diabetes is not a significant predictor of TLR at two years in patients treated with the TAXUS Stent.

Safety outcomes at two years showed that diabetic patients treated with the TAXUS Stent in the ARRIVE registry had similar rates of MI (3.1 percent vs. 2.5 percent, p=0.35, adjusted) and ARC definite/probable stent thrombosis (2.3 percent vs. 1.9 percent, p=0.34, adjusted) compared to non-diabetic patients, whether or not multivariate adjustment was used. The results also showed that diabetic patients had the expected increase in two-year mortality compared to patients without diabetes (7.0 percent vs. 3.9 percent, p

“Our extensive ARRIVE registries provide valuable insights into the benefits of the TAXUS Stent in treating diabetic patients who are often at higher risk for adverse events and repeat stenting procedures," said Donald S. Baim, M.D., chief medical and scientific officer at Boston Scientific. “The ARRIVE data demonstrated that the TAXUS Stent lessened the risk factor for clinical restenosis in the diabetic patients studied.”

The growing diabetic subset accounts for more than one-quarter of all coronary interventional procedures in the U.S. Diabetes is generally associated with an increased risk of overall mortality and cardiovascular events. In addition, patients with diabetes are more likely than non-diabetic patients to require repeat procedures due to a higher incidence of restenosis following angioplasty and stenting.

In the U.S., the TAXUS Stent is not specifically indicated for use in patients with diabetes.

For more information: www.bostonscientific.com

Related Content

Titanium-Nitride-Oxide Stent Superior to Bioabsorbable DES in Acute Coronary Syndrome Patients

Image courtesy of Hexacath

News | Stents Drug Eluting | May 31, 2018
Late-breaking trial results presented at the EuroPCR Congress, May 21-24 in Paris, France, found the Optimax titanium-...
Orsiro DES Shows Lowest Two-Year Target Lesion Failure in BIO-RESORT Trial
News | Stents Drug Eluting | May 31, 2018
Two-year outcome data from the BIO-RESORT randomized controlled trial were presented in a late-breaking clinical trials...
OCT Reveals Excellent Healing Profile for Complex CAD Patients With Resolute Onyx DES
News | Stents Drug Eluting | May 29, 2018
Investigators recently unveiled clinical data from the independently run Onyx 1-Month OCT Study showing strong early...
Abbott's Xience Sierra Stent Receives FDA Approval
Technology | Stents Drug Eluting | May 25, 2018
Abbott announced it received approval from the U.S. Food and Drug Administration (FDA) for Xience Sierra, the newest...
Medtronic Launches 2 mm Onyx DES
Technology | Stents Drug Eluting | February 26, 2018
February 26, 2018 – Designed specifically for small vessels, Medtronic plc announced U.S.
Detroit Medical Center Heart Hospital Uses Michigan's First EluNIR Drug-Eluting Stent
News | Stents Drug Eluting | February 19, 2018
February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently beca
Biotronik Symposium Highlights Differing Roles of Drug-Eluting Stents and Magnesium Scaffolds in Clinical Practice
News | Stents Drug Eluting | January 25, 2018
January 25, 2018 – Data presented at the Biotronik-sponsored...
The Abbott Absorb Bioresorbable Vascular Scaffold (BVS) bioabsorbable stent.

The Abbott Absorb Bioresorbable Vascular Scaffold (BVS).

Feature | Stents Drug Eluting | January 17, 2018 | Dave Fornell
There was no shortage of interest in bioresorbable stent technologies at the many sessions offered on this topic or b
Cordis and Medinol Announce FDA Approval of EluNIR Drug-Eluting Stent System
Technology | Stents Drug Eluting | December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
The Xience Sierra stent.
Technology | Stents Drug Eluting | November 09, 2017
November 9, 2017 — Abbott received European CE mark for Xience Sierra, the newest generation of the company's Xience
Overlay Init